#ASC47

Thiard News@F4F

@newsen.bsky.social

5 months ago

Ascletis Unveils Promising Weight Loss Drug ASC47 Showing Significant Efficacy in Obesity Management Ascletis Pharma's ASC47, combined with semaglutide, shows up to 56.2% greater weight loss in obese participants compared to semaglutide alone, revolutionizing obesity treatment.

Ascletis Unveils Promising Weight Loss Drug ASC47 Showing Significant Efficacy in Obesity Management #Hong_Kong #Semaglutide #Ascletis #ASC47

Thiard News@F4F

@newsen.bsky.social

6 months ago

Ascletis Unveils Promising New Weight Loss Treatment Featuring ASC47 and ASC31 Ascletis Pharma presents effective preclinical results for ASC47 and ASC31, showing superior weight loss in obese models compared to existing treatments.

Ascletis Unveils Promising New Weight Loss Treatment Featuring ASC47 and ASC31 #China #Hong_Kong #Ascletis #ASC47 #ASC31

Thiard News@F4F

@newsen.bsky.social

7 months ago

Ascletis Unveils ASC47: A Revolutionary Drug for Obesity Management with Enhanced Efficacy Over Semaglutide Ascletis has announced promising results for ASC47, a muscle-preserving drug for obesity showing superior weight loss compared to Semaglutide in mice. This breakthrough could change obesity treatment.

Ascletis Unveils ASC47: A Revolutionary Drug for Obesity Management with Enhanced Efficacy Over Semaglutide #Hong_Kong #obesity #tirzepatide #ASC47

Thiard News@F4F

@newsen.bsky.social

8 months ago

Ascletis Successfully Completes Dosing in U.S. Obesity Study with Novel Drug Combination Ascletis Pharma has completed participant dosing in a clinical trial combining ASC47 and Semaglutide to treat obesity. Topline results are expected late 2025.

Ascletis Successfully Completes Dosing in U.S. Obesity Study with Novel Drug Combination #United_States #N/A #Semaglutide #Ascletis #ASC47

Thiard News@F4F

@newsen.bsky.social

9 months ago

Ascletis Showcases Breakthrough Research on Diabetes Treatment at 85th ADA Scientific Sessions Ascletis Pharma presents cutting-edge findings on its diabetes treatment candidates ASC30 and ASC47 at the upcoming ADA Scientific Sessions in Chicago.

Ascletis Showcases Breakthrough Research on Diabetes Treatment at 85th ADA Scientific Sessions #USA #Chicago #Ascletis #ASC47 #ASC30

Thiard News@F4F

@newsen.bsky.social

9 months ago

Ascletis Initiates U.S. Clinical Study for New Obesity Treatment with ASC47 and Semaglutide Ascletis Pharma has started a clinical study in the U.S. to assess the safety and efficacy of combining ASC47 and Semaglutide for treating obesity, enhancing weight loss while preserving muscle.

Ascletis Initiates U.S. Clinical Study for New Obesity Treatment with ASC47 and Semaglutide #USA #Semaglutide #Various_Locations #Ascletis #ASC47

Thiard News@F4F

@newsen.bsky.social

10 months ago

Ascletis Showcases Innovative ASC47 Weight Loss Drug Research at European Congress on Obesity At the 32nd European Congress on Obesity, Ascletis will present findings on ASC47, a unique weight loss drug that aims to preserve muscle while promoting fat loss.

Ascletis Showcases Innovative ASC47 Weight Loss Drug Research at European Congress on Obesity #China #Hong_Kong #ASC47 #Ascletis_Pharma #ECO_2025

Thiard News@F4F

@newsen.bsky.social

1 year ago

Ascletis Reveals Breakthrough Phase Ib Results for ASC47 Weight Loss Drug in the US and Australia Ascletis has released promising results from Phase Ib studies of ASC47, a novel obesity treatment, showcasing its efficacy and safety in patients.

Ascletis Reveals Breakthrough Phase Ib Results for ASC47 Weight Loss Drug in the US and Australia #USA #Hong_Kong #ASC47 #Obesity_Treatment #Ascletis_Pharma

Thiard News@F4F

@newsen.bsky.social

1 year ago

Ascletis Unveils ASC47: A Groundbreaking Weight Loss Treatment for Obesity Ascletis has announced impressive results for ASC47, a muscle-preserving weight loss drug which, in trials, outperformed existing treatments for obesity.

Ascletis Unveils ASC47: A Groundbreaking Weight Loss Treatment for Obesity #Hong_Kong #obesity #Ascletis #ASC47